Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

On location

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...

Medicare Poised to Cover CAR T-Cell Therapy

Medicare may soon offer coverage of chimeric antigen receptor (CAR) T-cell therapy for patients with cancer, but with considerable restrictions that aim to rein...

JULIET Analysis Finds Durable Responses With Tisagenlecleucel in DLBCL

Half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded to tisagenlecleucel, and approximately two-thirds of responders are expected to remain...

Ibrutinib and Obinutuzumab Combo Granted Approval for CLL/SLL

The U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib and obinutuzumab for the treatment of patients with treatment-naïve chronic lymphocytic leukemia/small...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved a record-breaking number of drugs, several of which were indicated for the...

Study of Single-Agent Nivolumab in Patients With Relapsed/Refractory DLBCL Fails to Meet Endpoint

Treatment with single-agent nivolumab was associated with “disappointingly low” response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to...

Combination of Ibrutinib and Nivolumab Appears Similar to Single-Agent Therapy in Early-Phase Trial

According to results from a phase I/II trial published in Lancet Haematology, treatment with a combination of ibrutinib and the checkpoint inhibitor nivolumab was...
On location

Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL

For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of the BCL2 protein, combining the BCL2 inhibitor venetoclax with...
On location

Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL

For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response rates and prolonged time to next treatment, compared with...

Is the Era of Traditional Chemotherapy for Hodgkin Lymphoma Over?

Treatment of Hodgkin lymphoma (HL) has been one of the greatest success stories in oncology, with the invention of radiation therapy and combination chemotherapy...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.